



[REDACTED]
[REDACTED]

MHRA

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

www.gov.uk/mhra

19th March 2024

Dear [REDACTED]

FOI 24/174

Thank you for your FOI request dated 21st February 2024, where you requested the following information:

1. How many Yellow Cards have been completed by the Trust, The Rotherham NHS Foundation Trust, S60 2UD.

April 2023 - 31 January 2024

April 2022 - March 2023

April 2021 - March 2023

2. What were the medicines /products involved and the reactions reported?

3. Is it possible to self-search for this information on a regular basis and not to trouble your team?

4. I have seen bar chart showing how one's trust compares with other trusts in the region. Is this information still available and if so, how can I obtain it?

We will address each of your questions in turn.

1. I can confirm that up to and including 12/03/2024, the MHRA have received the following number of UK spontaneous suspected adverse reaction reports from The Rotherham NHS Foundation Trust, S60 2UD:
 - April 2021 - March 2023: 82 cases
 - April 2022 - March 2023: 30 cases
 - April 2023 - 31 January 2024: 28 cases
2. Please find attached Table 1 and 2, which contains the number of ADR reports relating to the reported adverse drug reactions, and drug substances, respectively, reported to The Rotherham NHS Foundation Trust, S60 2UD between April 2021– 31/03/2024 (inclusive). Please note that



the sum of reports in these tables will not be equal to the total number of unique reports as one report may contain more than one reported adverse drug reaction and multiple suspect drugs. When considering the spontaneous data within this response, it is important to be aware of the following points:

- A reported reaction does not necessarily mean it has been caused by the reported drug, only that the reporter had a suspicion it may have. The fact that symptoms occur after use of a vaccine or medicine, and are reported via the Yellow Card scheme, does not in itself mean that they are proven to have been caused by it. Underlying or concurrent illnesses may be responsible and such events can also be coincidental.
 - It is also important to note that the number of reports received via the Yellow Card scheme does not directly equate to the number of people who suffer adverse reactions and therefore cannot be used to determine the incidence of a reaction or compare the safety profile of different medicines and vaccines. Reporting rates are influenced by the seriousness of the reaction, their ease of recognition, the extent of use and may be stimulated by promotion and publicity. Reporting tends to be highest for newly introduced medicines, vaccines during the first one to two years on the market and then falls over time.
3. The MHRA does not routinely publish or provide NHS Trusts with data relating to Yellow Card submissions. The MHRA does however run 5 regional Yellow Card Centres whose primary objective is to promote, support and stimulate local reporting of suspected adverse drug reactions. These regional Yellow Card Centres may use Yellow Card reporting statistics from different NHS Trusts or GP practices as part of their role to engage with local healthcare professionals and organisations. The Rotherham NHS Foundation Trust would fall under the remit of the Yellow Card Centre Northern & Yorkshire who can be contacted at nuth.yccnorthernandyorkshire.
4. Please refer to the response to question 3.

We hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

Yours sincerely,

FOI Team,
Safety and Surveillance

The MHRA information supplied in response to your request is subject to Crown copyright. The FOIA only entitles you to access to MHRA information.

For information on the reproduction or re-use of MHRA information, please visit <https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information>

If you have a query about this email, please contact us. If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the Agency who has not previously been involved in your request. If you wish to pursue that option please write to the Communications Directorate, 4-T, Medicines and Healthcare products Regulatory Agency, (via



Medicines & Healthcare products
Regulatory Agency



this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Copyright notice

The information supplied in response to your request is the copyright of MHRA and/or a third party or parties, and has been supplied for your personal use only. You may not sell, resell or otherwise use any information provided without prior agreement from the copyright holder.